The Week Ahead: Hom...
Health Care: Drugs
Vertex Pharmaceuticals (VRTX: NASDAQ)
$79.49 1.60 | 2.05%
05/17/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 489.41M | 475.32M | 243.20M | 446.66M |
| Receivables | 143.25M | 183.14M | 12.53M | 9.60M |
| Inventories | 30.46M | 112.43M | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 1.59B | 1.33B | 1.06B | 1.31B |
| Property, Plant & Equipment, Gross | 730.29M | 404.24M | 319.65M | 284.00M |
| Accumulated Depreciation & Depletion | 296.68M | 271.06M | 247.32M | 221.73M |
| Property, Plant & Equipment, Net | 433.61M | 133.18M | 72.33M | 62.28M |
| Intangibles | 663.50M | 663.50M | 518.70M | 518.70M |
| Other Non-Current Assets | 41.60M | 45.36M | 51.27M | 41.38M |
| Total Non-Current Assets | 1.17B | 873.03M | 668.41M | 648.46M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 2.76B | 2.20B | 1.73B | 1.96B |
| Accounts Payable | 130.30M | 74.64M | 35.85M | 36.99M |
| Short Term Debt | 28.88M | 0.00 | 0.00 | 32.07M |
| Other Current Liabilities | 26.36M | 12.08M | 83.95M | 15.23M |
| Total Current Liabilities | 432.62M | 392.35M | 474.78M | 284.88M |
| Long Term Debt | 400.00M | 400.00M | 400.00M | 121.76M |
| Deferred Income Taxes | 280.37M | 243.71M | 160.28M | 160.28M |
| Other Non-Current Liabilities | 182.41M | 239.75M | 186.41M | 292.22M |
| Minority Interest | 55.90M | 11.60M | 0.00 | 0.00 |
| Total Non-Current Liabilities | 1.33B | 1.03B | 746.69M | 574.26M |
| Total Liabilities | 1.76B | 1.42B | 1.22B | 859.14M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 999.18M | 786.84M | 503.97M | 1.10B |
| Common Par | 2.15M | 2.07M | 2.02M | 1.98M |
| Additional Paid In Capital | 4.52B | 4.20B | 3.95B | 3.78B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -3.52B | -3.41B | -3.44B | -2.69B |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -550.00K | -1.05M | -1.07M | -640.00K |
| Total Capitalization | 1.40B | 1.19B | 903.97M | 1.22B |
| Total Equity | 999.18M | 786.84M | 503.97M | 1.10B |
| Total Liabilities & Stock Equity | 2.76B | 2.20B | 1.73B | 1.96B |
| Total Common Shares Outstanding | 217.29M | 209.30M | 203.52M | 199.96M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 211.95M | 204.89M | 200.40M | 173.26M |
| Diluted Weighted Shares Outstanding | 211.95M | 208.81M | 200.40M | 173.26M |
| Number of Employees | 2200 | 2000 | 1691 | 1422 |
| Number of Part-Time Employees | 0 | 0 | 0 | 10 |
Portfolios with VRTX
- Portfolio NameUser Type
- UserDC
- UserPortfolio
- ProDaniel Loeb - Third Point
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
- ContributorEarnings Short Squeeze Play...
- Contributor10 Hep C Stocks on Wall Str...
Latest VRTX Headlines from TheStreet
- Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Laggard 05.16.13 | 05:05 pm
- 3 Stocks Underperforming Today In The Drugs Industry 05.15.13 | 01:05 pm
- 3 Stocks Improving Performance Of The Health Care Sector 05.06.13 | 01:05 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard 05.03.13 | 05:05 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard 04.26.13 | 05:04 pm
- Vertex CFO Rings Register On $35 Million Insider Sale 04.24.13 | 07:04 am
- 'Mad Money' Lightning Round: Apache Is a Dog 04.24.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Looking for Winners in Unlikely Places 04.23.13 | 08:04 pm
- 4 Stocks Pushing The Drugs Industry Downward 04.22.13 | 01:04 pm
- Vertex Stock Falls On Unusually High Volume (VRTX) 04.22.13 | 12:04 pm
Press Releases for VRTX
- VX-787 Showed Significant Antiviral Activity And Reduced The Severity And Duration Of Influenza Symptoms In Phase 2 Challenge Study - Business Wire 03.04.13 | 08:03 am
- Vertex Announces Webcasts Of Its Presentations At Two Investor Conferences - Business Wire 02.27.13 | 04:02 pm
- Vertex Announces Initiation Of Pivotal Phase 3 Program Of VX-809 In Combination With Ivacaftor For The Treatment Of People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 02.26.13 | 04:02 pm
- Republic Of Ireland Approves Funding For KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 02.01.13 | 12:02 pm
- Vertex Reports Full-Year And Fourth Quarter 2012 Financial Results And Provides Updates On Key Development Programs - Business Wire 01.29.13 | 04:01 pm
- Vertex To Report Fourth Quarter And Full Year 2012 Financial Results On Tuesday, January 29 - Business Wire 01.15.13 | 04:01 pm
- Vertex Outlines Corporate Strategy And Defines Key 2013 Business Priorities - Business Wire 01.06.13 | 05:01 pm
- NHS In England Funds KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 12.19.12 | 09:12 am
- Vertex Announces Update To U.S. Prescribing Information For INCIVEK® (telaprevir) - Business Wire 12.19.12 | 08:12 am
- Health Canada Approves KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People With A Specific Genetic Mutation (G551D) - Business Wire 12.03.12 | 08:12 am
Partner Headlines for VRTX
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Inside Wall Street: closer to a cystic fibrosis cure - MSN Money 05.03.13 | 01:05 pm
- Gilead's HCV Drug Pipeline Outshines Weak Q1 Results - Investor's Business Daily 05.02.13 | 06:05 pm
- Stocks Down In Rising Trade; Nuance Communications Falls - Investor's Business Daily 04.30.13 | 10:04 am
- Vertex Pharmaceuticals Earnings: Here’s Why Shares are Up Now - Wall St. Cheat Sheet 04.30.13 | 06:04 am
- Vertex Pharmaceuticals Incorporated Earnings Preview: Can This Streak Finally End? - Wall St. Cheat Sheet 04.29.13 | 11:04 am
- Weekly Preview: Focus Shifts from Earnings to Economy - Benzinga 04.26.13 | 04:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,233.55 up 27.49 points - NASDAQ 04.22.13 | 08:04 pm
- Stocks Improve Late Session; Dow Industrials Turn Green - Investor's Business Daily 04.22.13 | 02:04 pm
- Biotech Stocks Get A Turbo Boost From Vertex - Seeking Alpha 04.20.13 | 09:04 am
